2022 Annual Meeting Virtual Experience | ITU.9 - Industry Therapeutic Update from Horizon Therapeutics: UPLIZNA® (inebilizumab-cdon): A Next-Era Treatment Option for NMOSD

Date Sunday 04/24/22

Time 08:00 AM - 06:30 PM EDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Topic(s) General Neurology

Learning Objectives This program includes an overview of neuromyelitis optica spectrum disorder (NMOSD) and the central role of B cells in disease pathogenesis. It will review the benefits of targeting CD19+ B cells for optimal disease management, the demonstrated short- and long-term efficacy and safety of UPLIZNA, as well as an exploration of real-world use of UPLIZNA through a patient case. Please note that no CME will be given by any accredited organization for attending. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2022 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Program Materials Program Evaluations

Event Timeline
08:00 AM - 09:00 AM EDT	Speaker	Industry Therapeutic Update from Horizon Therapeutics: UPLIZNA® (inebilizumab-cdon): A Next-Era Treatment Option for NMOSD Patricia Cole

Faculty Disclosures
Patricia Cole	No disclosure on file